Disease-modifying drug therapies

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue SUPPL. 1, 2004, Pages 68-75

  Brooks, Benjamin R ^a   Sanjak, Mohammed ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CREATININE; DECONGESTIVE AGENT; DESICCANT; NORTRIPTYLINE; PLACEBO; QUININE; RILUZOLE; SALBUTAMOL; ZINC;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; DATA BASE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; FUNCTIONAL ASSESSMENT; HUMAN; LONG TERM CARE; ONSET AGE; OUTCOMES RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADULT; AGE FACTORS; AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; ANTIRHEUMATIC AGENTS; BULBAR PALSY, PROGRESSIVE; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; RILUZOLE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 6444231956     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/17434470410019898     Document Type: Article

References (28)

1. Brook BR, Juhasz-Poscine K, Waclawik A et al. Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: beta-2 adrenergic agonists. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 1 (Suppl 4) 2000; 45-53; discussion 53-54.
2. Carter GT, Krivickas LS, Weydt P, Weiss MD, Miller RG. Drug therapy for amyotrophic lateral sclerosis: where are we now? Drugs 2003; 6(2): 147-153.
3. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V, Riluzole/ALS Study Group II. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. Journal of Neurology 2002; 249(5): 609-615.
4. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New England Journal of Medicine 1994; 330(9): 585-591.
5. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347(9013): 1425-1431.
6. Miller RG, Bouchard JP, Duquette P et al. Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II. Neurology 1996; 47(Suppl 2): S86-90; discussion S90-92.
7. Dunlop J, Beal F, McIlvain H, She Y, Howland DS. Impaired spinal cord glutamate transport capacity and reduced sensitivity to riluzole in a transgenic superoxide dismutase mutant rat model of amyotrophic lateral sclerosis. Journal of Neuroscience 2003; 23(5): 1688-1696.
8. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Archives of Neurology 1998; 55(4): 526-528.
9. Desnuelle C, Dib M, Cartel C, Favier A. A double-blind, placebo controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001; 2(1): 9-18.
10. Debove C, Zeisser P, Salzman PM, Powe LK, Truffinet P. The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2001; 2(3): 153-158.
11. Lacomblez L, Bensimon G, Leigh PN et al. and the ALS Study Groups I and II. Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2002; 3(1): 23-29.
12. Meininger V, Dib M, Aubin F, Jourdain C, Zeisser P. The Riluzole Early Access Programme: descriptive analysis of 844 patients in France. ALS/Riluzole Study Group III. Journal of Neurology 1997; 244 (Suppl 2): S22-25.
13. Pongratz D, Neundorfer B, Fischer W. German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS). Journal of the Neurological Sciences 2000; 180(1-2): 82-85.
14. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis: a population-based study in Ireland, 1996-2000. Journal of Neurology 2003; 250(4): 473-479.
15. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2002; 3(1): 15-21.
16. Miller RG, Anderson FA Jr, Bradley WG et al. The ALS patient care database: goals, design, and early results. ALS CARE Study Group. Neurology 2000; 54(1): 53-57.
17. Barnett D. Riluzole for motor neuron disease. Reply from chairman of appraisal committee at NICE. Br Med J 2001; 323(7312): 573.
18. Bryan S, Barton P, Burls A. The clinical effectiveness and cost-effectiveness of riluzole for motor neuron disease: an update. National Institute for Clinical Excellence Health Technology Assessment Report Part 2, 2001; pp. 1-6. http://www.nice.org.uk/pdf/Riluzole_htarep_part2.pdf
19. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Systematic Reviews 2000; (2): CD001447.
20. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Systematic Reviews 2001; (2): CD001447.
21. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Systematic Reviews 2002; (2): CD001447.
22. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 2003; 4(3): 191-206.
23. Sandercock J, Burls A, Hyde C et al. Riluzole for motor neuron disease: more trials are needed. Br Med J 2001; 322(7297): 1305.
24. Stewart A, Sandercock J, Bryan S, Hyde C, Fry-Smith A, Burls A. The clinical effectiveness and cost-effectiveness of riluzole for motor neuron disease: an update. National Institute for Clinical Excellence Health Technology Assessment Report Part 1, 2000. pp. 1-75. http://www.nice.org.uk/pdf/Riluzole_htarep_part1.pdf
25. Stewart R. Riluzole for motor neuron disease: ambiguous diagnostic criteria mean that wide variations in eligibility may still persist. Br Med J 2001; 322(7297): 1305-1306.
26. Wheatley K, Cray R. Riluzole for motor neuron disease. Large, more economical trial is needed. Br Med J 2001; 322(7297): 1305.
27. Stewart A, Sandercock J, Bryan S et al. The clinical effectiveness and cost-effectiveness of riluzole for motor neuron disease: a rapid and systematic review. Executive Summary. Health Technology Assessment 2001; 5(2): 1-4. www.ncchta.org/pdfexecs/summ502.pdf
28. Massof RW, Finklestein D. A two-stage hypothesis for the natural course of retinitis pigmentosa. In Zrenner E, Krastel H, Goebel H (Eds). Research in Retinitis Pigmentosa. Advances in the Biosciences 1987; 62: 29-58.